Trials / Not Yet Recruiting
Not Yet RecruitingNCT07091019
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | TKIs | There is no treatment allocation for NIS trials. Patients administered TKI (asciminib, bosutinib, dasatinib, imatinib, nilotinib) by prescription will be enrolled. |
Timeline
- Start date
- 2025-11-15
- Primary completion
- 2033-05-15
- Completion
- 2033-05-15
- First posted
- 2025-07-29
- Last updated
- 2025-07-29
Source: ClinicalTrials.gov record NCT07091019. Inclusion in this directory is not an endorsement.